RemoPro™ (treprostinil prodrug)
Remodulin® therapeutic platform
RemoPro™ (treprostinil prodrug)
We are conducting a series of Phase 1 studies to develop a new prodrug called RemoPro™ (treprostinil), which is intended to enable subcutaneous delivery of treprostinil analog therapy without the site pain currently associated with subcutaneous Remodulin® (treprostinil).
As a prodrug, RemoPro is designed to be inactive in the subcutaneous tissue, which should decrease or eliminate site pain, and to metabolize into treprostinil or a treprostinil analog once it is absorbed into the blood.
RemoPro™ is a development-stage product not approved for sale in any jurisdiction.